Medivation’s Prostate Cancer Drug Strong In Phase I/II
This article was originally published in The Pink Sheet Daily
Executive Summary
More precise criteria could help MDV3100 win where others failed, CEO tells “The Pink Sheet” DAILY.
You may also be interested in...
Several Prostate Cancer Drug Candidates Heading Into Home Stretch
In the next year or so, the race to develop new drug therapies for aggressive end-stage prostate cancer could heat up considerably, with several late-stage therapies due to report data in 2009 and early 2010
Several Prostate Cancer Drug Candidates Heading Into Home Stretch
In the next year or so, the race to develop new drug therapies for aggressive end-stage prostate cancer could heat up considerably, with several late-stage therapies due to report data in 2009 and early 2010
Several Prostate Cancer Drug Candidates Heading Into Home Stretch
In the next year or so, the race to develop new drug therapies for aggressive end-stage prostate cancer could heat up considerably, with several late-stage therapies due to report data in 2009 and early 2010.